StockNews.com assumed coverage on shares of MEI Pharma (NASDAQ:MEIP – Get Free Report) in a report released on Monday. The brokerage set a “buy” rating on the stock.
Separately, Stifel Nicolaus restated a “hold” rating and set a $7.00 price objective on shares of MEI Pharma in a research report on Friday, April 12th.
Read Our Latest Report on MEI Pharma
MEI Pharma Price Performance
MEI Pharma (NASDAQ:MEIP – Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($1.37) EPS for the quarter, beating the consensus estimate of ($1.38) by $0.01. MEI Pharma had a net margin of 39.06% and a return on equity of 48.32%. As a group, research analysts anticipate that MEI Pharma will post 3.22 EPS for the current year.
Institutional Trading of MEI Pharma
A hedge fund recently bought a new stake in MEI Pharma stock. National Bank of Canada FI bought a new position in MEI Pharma, Inc. (NASDAQ:MEIP – Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 6,000 shares of the company’s stock, valued at approximately $36,000. National Bank of Canada FI owned about 0.09% of MEI Pharma as of its most recent SEC filing. 52.38% of the stock is owned by institutional investors and hedge funds.
About MEI Pharma
MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.
Further Reading
- Five stocks we like better than MEI Pharma
- What Are Dividends? Buy the Best Dividend Stocks
- Chipotle Mexican Grill Stock Split: Where Does it Go From Here?
- Conference Calls and Individual Investors
- Arm Holdings and Micron: Top 2 AI Stocks to Buy and Hold
- How to Calculate Return on Investment (ROI)
- Best Buy Stock May Be Best Bought Before the Holiday Season
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.